Your browser doesn't support javascript.
loading
Impact of hematopoietic cell transplant frailty scale on transplant outcome in adults.
Salas, Maria Queralt; Atenafu, Eshetu G; Pasic, Ivan; Al-Shaibani, Eshrak; Bascom, Ora; Wilson, Leeann; Chen, Carol; Law, Arjun Datt; Lam, Wilson; Novitzky-Basso, Igor; Kim, Dennis Dong Hwan; Gerbitz, Armin; Viswabandya, Auro; Michelis, Fotios V; Lipton, Jeffrey Howard; Mattsson, Jonas; Alibhai, Shabbir; Kumar, Rajat.
Afiliação
  • Salas MQ; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Atenafu EG; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Pasic I; Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.
  • Al-Shaibani E; Department of Biostatistics, Princes Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Bascom O; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Wilson L; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Chen C; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Law AD; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Lam W; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Novitzky-Basso I; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Kim DDH; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Gerbitz A; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Viswabandya A; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Michelis FV; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Lipton JH; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Mattsson J; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Alibhai S; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.
  • Kumar R; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Bone Marrow Transplant ; 58(3): 317-324, 2023 03.
Article em En | MEDLINE | ID: mdl-36526806
ABSTRACT
This prospective study designs an HCT Frailty Scale to classify alloHCT candidates into groups of frail, pre-frail, and fit, and to be implemented in the first consultation at no additional cost. The present scale is composed of the following eight variables Clinical Frailty Scale, Instrumental Activities of Daily Living, Timed Up and Go Test, Grip Strength, Self-Health Rated, Falls, Albumin, and C-Reactive Protein. The Frailty score of a patient is the weighted sum of scores for each item, with weights assigned according to the hazard ratios of a multivariable Cox proportional hazards model estimated and validated with data on OS as the dependent variable, and the scores of the eight variables as explanatory ones, from 298 adults split into training (n = 200) and validation (n = 98) sets. For clinical use, the scale scores were transformed into three categories scale score ≤1 fit; 15.5 frail. The estimated probabilities of 1-year OS in each group of frailty, were, respectively 83.7%, 48.5%, and 16.5% (p < 0.001). In the validation cohort, the respective values were 90.3%, 69.5%, and 46.2% (p < 0.001). Pending further external validations, the HCT Frailty Scale is a low cost-highly informative prognostic signal of outcomes at the pre-transplant stage.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Fragilidade Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Humans Idioma: En Revista: Bone Marrow Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Fragilidade Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Humans Idioma: En Revista: Bone Marrow Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá